Exploring potential associations between blood metabolites and cirrhosis risk: a Mendelian randomization and LC–MS/MS analysis
-
By
-
Duoduo Lv
-
Ning Han
-
Hong Tang
-
July 2, 2026
-
Clinical Scorecard: Investigating the Links Between Blood Metabolites and Cirrhosis Risk: A Mendelian Randomization and Targeted Metabolomics Approach
At a Glance
| Category | Detail |
|---|
| Condition | Cirrhosis |
| Key Mechanisms | Metabolic dysregulation and specific blood metabolites associated with cirrhosis risk. |
| Target Population | Individuals at risk for liver cirrhosis. |
| Care Setting | Clinical research and metabolomics analysis. |
Key Highlights
- Increased levels of 11 metabolites are associated with higher cirrhosis risk.
- Higher glutamine degradant levels are linked to lower cirrhosis risk (OR = 0.877).
- Lower glutamate and glutathione levels observed in cirrhosis patients compared to controls.
- Pathway analysis suggests involvement of arginine biosynthesis and proline metabolism in cirrhosis.
- Study combines Mendelian randomization with targeted metabolomics for novel insights.
Guideline-Based Recommendations
Diagnosis
- Utilize metabolite profiling as a potential biomarker for cirrhosis risk assessment.
Management
- Consider targeting metabolic pathways for potential therapeutic strategies in cirrhosis.
Monitoring & Follow-up
- Monitor specific blood metabolites for changes in cirrhosis risk.
Risks
- Increased risk of cirrhosis associated with specific metabolite levels.
Patient & Prescribing Data
Patients with liver cirrhosis and healthy controls.
Metabolite alterations may inform future therapeutic approaches.
Clinical Best Practices
- Incorporate metabolomics in research to understand cirrhosis mechanisms.
- Use Mendelian randomization to infer causal relationships in metabolic studies.
Related Resources & Content
